Increased serum IL-36α and IL-36γ levels in patients with systemic lupus erythematosus: Association with disease activity and arthritis.
Int Immunopharmacol
; 58: 103-108, 2018 May.
Article
em En
| MEDLINE
| ID: mdl-29571080
ABSTRACT
IL-36 cytokines (IL-36Ra, IL-36α, IL-36ß and IL-36γ) belong to the IL-1 family and have been linked to several autoimmune diseases. However, little is known about the relationships between systemic lupus erythematosus (SLE) and IL-36 cytokines. In this study, serum IL-36 cytokine levels were determined by enzyme-linked immunosorbent assay (ELISA), and their associations with SLE-related parameters were analyzed in 72 SLE patients and 63 healthy controls. Additionally, IL-36 cytokine mRNA levels were assessed in 30 of 72 SLE patients and 20 of 63 healthy controls using real-time quantitative reverse transcription polymerase chain reaction (RT-PCR). Compared to healthy controls, SLE patients had significantly decreased serum IL-36Ra levels (Pâ¯=â¯0.001) and markedly increased serum IL-36α and IL-36γ levels (Pâ¯=â¯0.004 and Pâ¯=â¯0.001, respectively). Serum IL-36α and IL-36γ levels were significantly higher in active SLE patients [SLE Disease Activity Index (SLEDAI) scoreâ¯≥â¯5] than in inactive patients (SLEDAI scoreâ¯≤â¯4) (Pâ¯=â¯0.020 and Pâ¯=â¯0.017, respectively). Serum IL-36α and IL-36γ levels were strongly correlated with SLEDAI score (râ¯=â¯0.308, Pâ¯=â¯0.008 and râ¯=â¯0.400, Pâ¯=â¯0.001, respectively) and complement C3 levels (râ¯=â¯-0.276, Pâ¯=â¯0.019 and râ¯=â¯-0.314, Pâ¯=â¯0.007, respectively). Moreover, SLE patients with arthritis had significantly higher serum IL-36α and IL-36γ levels than those without arthritis (Pâ¯=â¯0.001 and Pâ¯<â¯0.001, respectively). Our study indicates that the imbalanced antagonist/agonist profile of IL-36 cytokines may be linked to SLE pathogenesis. Furthermore, IL-36α and IL-36γ may participate in arthritis and may be good biomarkers of SLE disease activity.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite
/
Interleucina-1
/
Receptores de Interleucina
/
Lúpus Eritematoso Sistêmico
Tipo de estudo:
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Int Immunopharmacol
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
FARMACOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
China